Bing Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bing Yan has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Chengshuo Wang
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
6 shared publications - Luo Zhang
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
6 shared publications Chengshuo Wang
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China
2 shared publications- Di Wu
Department of Otolaryngology, Head and Neck Surgery, Beijing Tongren Hospital Capital Medical University Beijing China
2 shared publications - Linping Shu
Department of Otolaryngology, Head and Neck Surgery, Beijing Tongren Hospital Capital Medical University Beijing China
2 shared publications - Menglin Wang
Department of Otolaryngology, Head and Neck Surgery Beijing TongRen Hospital, Capital Medical University Beijing China
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
15(S)-HETE induces immune-related transcriptional changes in fibroblasts
Background: 15(S)-HETE, a bioactive lipid mediator derived from arachidonic acid, is closely associated with eosinophilic inflammation and recurrence in chronic rhinosinusitis with nasal polyps (CRSwNP). Nevertheless, its impact on fibroblast-associated transcriptional regulation remains poorly characterized. Objective: To characterize the transcriptional and immunologic alterations in fibroblasts following 15(S)-HETE exposure. Methods: Human fibroblasts (MRC-5) were exposed to either 15(S)-HETE or a dimethyl sulfoxide vehicle control before RNA sequencing. Differential expression analysis was combined with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway annotation to characterize functional alterations. Pathway-level transcriptional changes were additionally explored using gene set enrichment analysis and weighted gene co-expression network analysis. Fibroblast viability was further assessed with a Cell Counting Kit-8 assay. Results: Transcriptomic profiling of the 15(S)-HETE-treated group revealed 96 differentially expressed genes, consisting of 54 upregulated and 42 downregulated genes. Upregulated genes were enriched in cytokine-related and inflammatory pathways, particularly interleukin-17 and tumor necrosis factor signaling. In contrast, downregulated genes were mainly involved in interferon-mediated antiviral responses. Gene set enrichment analysis further revealed significant suppression of interferon-α and interferon-γ response signatures. Weighted Gene Co-expression Network Analysis identified inflammation-related gene modules associated with 15(S)-HETE stimulation, in which CXCL1 was upregulated. In addition, 15(S)-HETE treatment significantly increased fibroblast viability. Conclusion: 15(S)-HETE was associated with changes in fibroblast transcriptional programs, including reduced interferon-related signatures and increased cytokine signaling. These findings suggest a potential role for 15(S)-HETE in fibroblast-associated immune regulation relevant to CRSwNP.
- 21 October 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
Open Access15(S)-HETE induces immune-related transcriptional changes in fibroblasts
Background: 15(S)-HETE, a bioactive lipid mediator derived from arachidonic acid, is closely associated with eosinophilic inflammation and recurrence in chronic rhinosinusitis with nasal polyps (CRSwNP). Nevertheless, its impact on fibroblast-associated transcriptional regulation remains poorly characterized. Objective: To characterize the transcriptional and immunologic alterations in fibroblasts following 15(S)-HETE exposure. Methods: Human fibroblasts (MRC-5) were exposed to either 15(S)-HETE or a dimethyl sulfoxide vehicle control before RNA sequencing. Differential expression analysis was combined with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway annotation to characterize functional alterations. Pathway-level transcriptional changes were additionally explored using gene set enrichment analysis and weighted gene co-expression network analysis. Fibroblast viability was further assessed with a Cell Counting Kit-8 assay. Results: Transcriptomic profiling of the 15(S)-HETE-treated group revealed 96 differentially expressed genes, consisting of 54 upregulated and 42 downregulated genes. Upregulated genes were enriched in cytokine-related and inflammatory pathways, particularly interleukin-17 and tumor necrosis factor signaling. In contrast, downregulated genes were mainly involved in interferon-mediated antiviral responses. Gene set enrichment analysis further revealed significant suppression of interferon-α and interferon-γ response signatures. Weighted Gene Co-expression Network Analysis identified inflammation-related gene modules associated with 15(S)-HETE stimulation, in which CXCL1 was upregulated. In addition, 15(S)-HETE treatment significantly increased fibroblast viability. Conclusion: 15(S)-HETE was associated with changes in fibroblast transcriptional programs, including reduced interferon-related signatures and increased cytokine signaling. These findings suggest a potential role for 15(S)-HETE in fibroblast-associated immune regulation relevant to CRSwNP.
- Open Access
- 4 June 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
Dexamethasone modulates chemokine networks in murine type 2 inflammation model: Integration of network pharmacology and in vivo validation
Background: Type 2 nasal inflammatory diseases, including allergic rhinitis and chronic rhinosinusitis, are driven by cytokine and chemokine networks that sustain mucosal inflammation. Glucocorticoids serve as anti-inflammatory therapies, yet how they modulate chemokine networks has not been systematically evaluated using integrative approaches. Objective: This study aimed to elucidate the dose-dependent modulation of type 2 inflammation and specific chemokine pathways by dexamethasone in nasal inflammatory diseases, integrating network pharmacology with in vivo validation. Methods: Network pharmacology was used to predict core targets and pathways of dexamethasone related to type 2 nasal inflammation. Subsequently, in a papain-induced mouse model of type 2 inflammation, dexamethasone was administered intraperitoneally at 1, 5, or 10 mg/kg. Pharmacodynamic effects were assessed via evaluation of eosinophil and goblet cell infiltration, and the expression of inflammatory cytokines and chemokines. Results: Network pharmacology identified a chemokine-centered mechanism of glucocorticoids in allergic rhinitis/chronic rhinosinusitis, with CCL11 and the CCL2/CCR2 axis among hub nodes. In animal model, dexamethasone produced a clear dose–response hierarchy. Transcriptionally, 10 mg/kg dexamethasone significantly reduced Ccl2 and Ccr2 mRNA and downregulated Ccl11 and key type 2 cytokine/alarmin transcripts. At the protein level, CCL11 was significantly decreased at 5 mg/kg, whereas CCR2 was suppressed only at 10 mg/kg; CCL2 protein remained unchanged across groups. Systemically, leukocyte redistribution was evident from 5 mg/kg upward. Histologically, marked attenuation of nasal eosinophil infiltration and goblet cell hyperplasia was observed mainly at 10 mg/kg within the 4-day intervention window. Conclusion: Integrating network pharmacology with in vivo validation supports a chemokine-centered regulatory network engaged by dexamethasone in type 2 nasal inflammation. The suppression of CCL11 at intermediate doses identifies it as a sensitive pharmacodynamic indicator, whereas rapid histologic resolution in this acute model requires higher dosages within a short therapeutic window.
- 4 June 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
Open AccessDexamethasone modulates chemokine networks in murine type 2 inflammation model: Integration of network pharmacology and in vivo validation
Background: Type 2 nasal inflammatory diseases, including allergic rhinitis and chronic rhinosinusitis, are driven by cytokine and chemokine networks that sustain mucosal inflammation. Glucocorticoids serve as anti-inflammatory therapies, yet how they modulate chemokine networks has not been systematically evaluated using integrative approaches. Objective: This study aimed to elucidate the dose-dependent modulation of type 2 inflammation and specific chemokine pathways by dexamethasone in nasal inflammatory diseases, integrating network pharmacology with in vivo validation. Methods: Network pharmacology was used to predict core targets and pathways of dexamethasone related to type 2 nasal inflammation. Subsequently, in a papain-induced mouse model of type 2 inflammation, dexamethasone was administered intraperitoneally at 1, 5, or 10 mg/kg. Pharmacodynamic effects were assessed via evaluation of eosinophil and goblet cell infiltration, and the expression of inflammatory cytokines and chemokines. Results: Network pharmacology identified a chemokine-centered mechanism of glucocorticoids in allergic rhinitis/chronic rhinosinusitis, with CCL11 and the CCL2/CCR2 axis among hub nodes. In animal model, dexamethasone produced a clear dose–response hierarchy. Transcriptionally, 10 mg/kg dexamethasone significantly reduced Ccl2 and Ccr2 mRNA and downregulated Ccl11 and key type 2 cytokine/alarmin transcripts. At the protein level, CCL11 was significantly decreased at 5 mg/kg, whereas CCR2 was suppressed only at 10 mg/kg; CCL2 protein remained unchanged across groups. Systemically, leukocyte redistribution was evident from 5 mg/kg upward. Histologically, marked attenuation of nasal eosinophil infiltration and goblet cell hyperplasia was observed mainly at 10 mg/kg within the 4-day intervention window. Conclusion: Integrating network pharmacology with in vivo validation supports a chemokine-centered regulatory network engaged by dexamethasone in type 2 nasal inflammation. The suppression of CCL11 at intermediate doses identifies it as a sensitive pharmacodynamic indicator, whereas rapid histologic resolution in this acute model requires higher dosages within a short therapeutic window.
A Systematic Review of Multidimensional Predictors for Refractory Chronic Rhinosinusitis: Clinical, Systemic and Local Insights
The identification of predictive markers for refractory chronic rhinosinusitis with nasal polyps (RCRSwNP) is essential for advancing precision medicine. In this review, we systematically reviewed the literature on the predictive value of clinical characteristics and biomarkers for RCRSwNP, aiming to better understand current findings and support medical therapy for these patients. PubMed, EMBASE, The Cochrane Library, and Web of Science were searched from data inception until June 2024. The titles and abstracts of 6934 publications were screened, and finally, 54 eligible studies encompassing 450 markers, with categories including clinical characteristics, biomarkers, and multi‐marker panels (combinations of multiple markers to predict outcomes of CRSwNP) were evaluated. Data extraction and quality control were performed by two authors independently. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS)‐2 tool was used to assess the risk of bias of included studies. Markers were categorized by specimen type (systemic [in blood] vs. local [in nasal polyp tissues vs. in noninvasive samplings]) and analysis method (receiver operating characteristic‐based vs. group comparison‐based). Most markers demonstrated satisfactory diagnostic performance. Among demographic and clinical characteristics, the E/M ratio showed the highest diagnostic accuracy (area under the curve [AUC] = 0.947). Biomarkers derived from nasal polyp tissues—particularly Charcot–Leyden crystals (CLCs), and eosinophil counts or percentages, achieved high AUCs (up to 0.973). Noninvasive local markers, including cystatin SN and galectin‐10 protein levels in nasal secretions and CLC mRNA levels in nasal brushings, also showed strong predictive potential (AUCs > 0.930). Over 90% of the multi‐marker panels that integrated multiple markers demonstrated moderate to high predictive accuracy (AUCs > 0.700). This systematic review highlights critical predictors and their implications for the diagnosis and management of RCRSwNP, and emphasizes the need for standardized methodologies, larger cohorts, and validation studies to refine the predictive utility of these markers. Future advances in multi‐omics technologies and noninvasive sampling methods may further enhance the precision of RCRSwNP prediction, paving the way for improved therapeutic strategies.
A Systematic Review of Multidimensional Predictors for Refractory Chronic Rhinosinusitis: Clinical, Systemic and Local Insights
The identification of predictive markers for refractory chronic rhinosinusitis with nasal polyps (RCRSwNP) is essential for advancing precision medicine. In this review, we systematically reviewed the literature on the predictive value of clinical characteristics and biomarkers for RCRSwNP, aiming to better understand current findings and support medical therapy for these patients. PubMed, EMBASE, The Cochrane Library, and Web of Science were searched from data inception until June 2024. The titles and abstracts of 6934 publications were screened, and finally, 54 eligible studies encompassing 450 markers, with categories including clinical characteristics, biomarkers, and multi‐marker panels (combinations of multiple markers to predict outcomes of CRSwNP) were evaluated. Data extraction and quality control were performed by two authors independently. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS)‐2 tool was used to assess the risk of bias of included studies. Markers were categorized by specimen type (systemic [in blood] vs. local [in nasal polyp tissues vs. in noninvasive samplings]) and analysis method (receiver operating characteristic‐based vs. group comparison‐based). Most markers demonstrated satisfactory diagnostic performance. Among demographic and clinical characteristics, the E/M ratio showed the highest diagnostic accuracy (area under the curve [AUC] = 0.947). Biomarkers derived from nasal polyp tissues—particularly Charcot–Leyden crystals (CLCs), and eosinophil counts or percentages, achieved high AUCs (up to 0.973). Noninvasive local markers, including cystatin SN and galectin‐10 protein levels in nasal secretions and CLC mRNA levels in nasal brushings, also showed strong predictive potential (AUCs > 0.930). Over 90% of the multi‐marker panels that integrated multiple markers demonstrated moderate to high predictive accuracy (AUCs > 0.700). This systematic review highlights critical predictors and their implications for the diagnosis and management of RCRSwNP, and emphasizes the need for standardized methodologies, larger cohorts, and validation studies to refine the predictive utility of these markers. Future advances in multi‐omics technologies and noninvasive sampling methods may further enhance the precision of RCRSwNP prediction, paving the way for improved therapeutic strategies.
- Open Access
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
An anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial
To explore the therapeutic potential of blocking thymic stromal lymphopoietin (TSLP) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), we conducted a phase 1b/2a, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of CM326, a monoclonal antibody against TSLP. We enrolled 84 eligible patients with uncontrolled CRSwNP and stratified them based on baseline tissue eosinophil count. Patients are assigned to receive CM326 220 mg (n = 40) or placebo (n = 20) every 2 weeks (Q2W) and CM326 220 mg (n = 20) or placebo (n = 4) every 4 weeks (Q4W) for 16 weeks. Subsequently, all patients continue on CM326 220 mg Q2W or Q4W for an additional 36 weeks, followed by a 12-week follow up. Primary endpoints are safety of CM326 and change from baseline in NPS at week 16 in patients with eosinophilic CRSwNP (ECRSwNP). Main secondary endpoints include the change from baseline in NPS at week 16 in non-eosinophilic CRSwNP (nonECRwNP) and pharmacodynamic markers. Throughout the 64-week study, all treatment-emergent adverse events (TEAEs) are mild or moderate. CM326 Q2W improves NPS in patients with ECRSwNP compared with placebo at week 16 (mean difference [95% CI], −1.2 [−2.3 to −0.1], P = 0.04), with sustained benefits during the open-label and follow-up periods. Notably, peripheral blood and tissue eosinophil counts and concentrations of plasma IL-13 and IL-5 are reduced by week 16 with the treatment of CM326 Q2W versus placebo. A post-hoc analysis demonstrates that all participants with baseline TSLP > 330 fg/mL achieve a substantial reduction in NPS by week 16 with the treatment of CM326 Q2W (mean difference vs. placebo: −1.75 [95%CI, −3.06 to −0.44], P = 0.01). Overall, CM326 is well tolerated and effective in patients with uncontrolled ECRSwNP. A baseline plasma TSLP level of 330 fg/mL may serve as a predictive marker for treatment efficacy of CM326. ClinicalTrials.gov Identifier: NCT05324137.
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Open AccessAn anti-TSLP monoclonal antibody for uncontrolled CRSwNP: the DUBHE randomized clinical trial
To explore the therapeutic potential of blocking thymic stromal lymphopoietin (TSLP) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), we conducted a phase 1b/2a, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of CM326, a monoclonal antibody against TSLP. We enrolled 84 eligible patients with uncontrolled CRSwNP and stratified them based on baseline tissue eosinophil count. Patients are assigned to receive CM326 220 mg (n = 40) or placebo (n = 20) every 2 weeks (Q2W) and CM326 220 mg (n = 20) or placebo (n = 4) every 4 weeks (Q4W) for 16 weeks. Subsequently, all patients continue on CM326 220 mg Q2W or Q4W for an additional 36 weeks, followed by a 12-week follow up. Primary endpoints are safety of CM326 and change from baseline in NPS at week 16 in patients with eosinophilic CRSwNP (ECRSwNP). Main secondary endpoints include the change from baseline in NPS at week 16 in non-eosinophilic CRSwNP (nonECRwNP) and pharmacodynamic markers. Throughout the 64-week study, all treatment-emergent adverse events (TEAEs) are mild or moderate. CM326 Q2W improves NPS in patients with ECRSwNP compared with placebo at week 16 (mean difference [95% CI], −1.2 [−2.3 to −0.1], P = 0.04), with sustained benefits during the open-label and follow-up periods. Notably, peripheral blood and tissue eosinophil counts and concentrations of plasma IL-13 and IL-5 are reduced by week 16 with the treatment of CM326 Q2W versus placebo. A post-hoc analysis demonstrates that all participants with baseline TSLP > 330 fg/mL achieve a substantial reduction in NPS by week 16 with the treatment of CM326 Q2W (mean difference vs. placebo: −1.75 [95%CI, −3.06 to −0.44], P = 0.01). Overall, CM326 is well tolerated and effective in patients with uncontrolled ECRSwNP. A baseline plasma TSLP level of 330 fg/mL may serve as a predictive marker for treatment efficacy of CM326. ClinicalTrials.gov Identifier: NCT05324137.
- 7 May 2024
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (8) , 4221-4230
The diagnostic value of image-enhanced endoscopy system in sinonasal inverted papilloma
Purpose This study aimed to evaluate the diagnostic value of image-enhanced endoscopy (IEE) in detecting sinonasal inverted papilloma (SNIP). Methods Overall, 86 patients with unilateral nasal papillary or lobulated neoplasms were included between July 2018 and June 2019. All patients underwent IEE examinations, and the diagnosis of all neoplasms was confirmed through postoperative pathology. Logistic regression analysis was conducted to screen for independent predictors of various types of vascular patterns of SNIP. Furthermore, a prognostic nomogram was constructed using the independent predictors screened by logistic regression analysis to evaluate its usefulness in distinguishing SNIP from nasal polyp (NP) and papillary mucosa folds (PMF). Results In total, 86 consecutive cases were observed, including 37 with SNIP, 40 with NP, and 9 with PMF. Logistic regression analysis showed that spot, corkscrew, and multilayered vascular patterns were independent predictors of SNIP diagnosis. Furthermore, a nomogram comprising the three independent risk factors was constructed with scores of 5, 2, and 3. The area under the receiver operating characteristic curve for predicting SNIP was 0.954, 0.66, 0.71, and 0.76 for the nomogram model, spot vascular pattern, corkscrew vascular pattern, and multilayered vascular pattern, respectively. Conclusion The nomogram model based on spot, corkscrew, and multilayered vascular patterns in SNIP observed using IEE can be a useful diagnostic tool for predicting and distinguishing between NP and PMF.
- 7 May 2024
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (8) , 4221-4230
The diagnostic value of image-enhanced endoscopy system in sinonasal inverted papilloma
Purpose This study aimed to evaluate the diagnostic value of image-enhanced endoscopy (IEE) in detecting sinonasal inverted papilloma (SNIP). Methods Overall, 86 patients with unilateral nasal papillary or lobulated neoplasms were included between July 2018 and June 2019. All patients underwent IEE examinations, and the diagnosis of all neoplasms was confirmed through postoperative pathology. Logistic regression analysis was conducted to screen for independent predictors of various types of vascular patterns of SNIP. Furthermore, a prognostic nomogram was constructed using the independent predictors screened by logistic regression analysis to evaluate its usefulness in distinguishing SNIP from nasal polyp (NP) and papillary mucosa folds (PMF). Results In total, 86 consecutive cases were observed, including 37 with SNIP, 40 with NP, and 9 with PMF. Logistic regression analysis showed that spot, corkscrew, and multilayered vascular patterns were independent predictors of SNIP diagnosis. Furthermore, a nomogram comprising the three independent risk factors was constructed with scores of 5, 2, and 3. The area under the receiver operating characteristic curve for predicting SNIP was 0.954, 0.66, 0.71, and 0.76 for the nomogram model, spot vascular pattern, corkscrew vascular pattern, and multilayered vascular pattern, respectively. Conclusion The nomogram model based on spot, corkscrew, and multilayered vascular patterns in SNIP observed using IEE can be a useful diagnostic tool for predicting and distinguishing between NP and PMF.
- 8 February 2020
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 16 (3) , 293-310
The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory airway disease characterized as tight junction loosening, inflammation, and mucosal remodeling. Epithelial cells form a barrier against allergens, bacteria, and proteases, and can also trigger or enhance the immune response by releasing various inflammatory mediators including cytokines, chemokines, and secreted proteins to promote the pathogenesis of CRSwNP. Areas covered: We review the epithelium-derived cytokine and secreted protein networks driving CRSwNP, and discuss these mediators in a cellular context. We illustrate their roles as potential mediators-biomarkers in clinical practice, which may help to understand the mechanisms underlying the pathologies of different endotypes of CRSwNP and to improve treatment outcomes in patients with CRSwNP based on the development of novel predictors for CRSwNP management. Expert opinion: The understanding of the role of epithelium-derived inflammatory mediators helps to investigate the pathophysiological mechanisms of CRSwNP endotypes. An increasing number of studies show that these mediators target immune cells and promote the recruitment, activation or regulation of the proliferation or apoptosis of these cells. Based on this achievement, further investigations are necessary to explore the multi-dimensional role of epithelium-derived inflammatory mediators in CRSwNP.
- 8 February 2020
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 16 (3) , 293-310
The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory airway disease characterized as tight junction loosening, inflammation, and mucosal remodeling. Epithelial cells form a barrier against allergens, bacteria, and proteases, and can also trigger or enhance the immune response by releasing various inflammatory mediators including cytokines, chemokines, and secreted proteins to promote the pathogenesis of CRSwNP. Areas covered: We review the epithelium-derived cytokine and secreted protein networks driving CRSwNP, and discuss these mediators in a cellular context. We illustrate their roles as potential mediators-biomarkers in clinical practice, which may help to understand the mechanisms underlying the pathologies of different endotypes of CRSwNP and to improve treatment outcomes in patients with CRSwNP based on the development of novel predictors for CRSwNP management. Expert opinion: The understanding of the role of epithelium-derived inflammatory mediators helps to investigate the pathophysiological mechanisms of CRSwNP endotypes. An increasing number of studies show that these mediators target immune cells and promote the recruitment, activation or regulation of the proliferation or apoptosis of these cells. Based on this achievement, further investigations are necessary to explore the multi-dimensional role of epithelium-derived inflammatory mediators in CRSwNP.